Skip to main content

DNAVision to Offer DiaGenic Gene Expression Tests

NEW YORK (GenomeWeb News) – DiaGenic said today that lab services firm DNAVision will offer the firm’s blood-based gene expression tests for early detection of breast cancer and Alzheimer’s disease.
 
The Oslo-based molecular diagnostics firm said that DNAVision would offer the tests through its CLIA/ISO17025-certified facilities.
 
DiaGenic said it is in the process of introducing the breast cancer test in India. It expects to CE Mark the tests early next year and then seek clearance in the US sometime in the future.
 
“In parallel to this agreement, we are finalizing the distribution channels in preparation for a full European launch in early next year following CE marking of both the breast cancer and the Alzheimer’s disease test,” DiaGenic CEO Erik Christensen said in a statement.
 

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.